Drug intelligence / Profile preview

Xue Jie

Development stage: Preclinical
Administration: Topical, Oral

Overview

Xue Jie, also known as Dragon's Blood or Sanguis Draconis, is a traditional Chinese medicine (TCM) ingredient derived from the reddish resin of certain plants, primarily from the Daemonorops genus (e.g., Daemonorops draco). It is traditionally used to invigorate blood circulation, dispel blood stasis, alleviate pain, stop bleeding, and promote tissue regeneration. It is often applied topically for wound healing and internally for conditions related to blood stasis, such as traumatic injuries, abdominal pain, and gynecological issues.

Other names: Dragon's BloodSanguis DraconisDaemonorops draco resin

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MMP3 (Matrix metalloproteinase-3)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)SP (Substance P)TIMP1 (Metalloproteinase inhibitor 1)TGFB1 (Transforming growth factor Beta-1 proprotein)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on Xue Jie.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xue Jie.